Loading…

Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis

While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of...

Full description

Saved in:
Bibliographic Details
Published in:Central-European journal of immunology 2018-01, Vol.43 (3), p.289-294
Main Authors: Sikorska, Dorota, Rutkowski, Rafał, Łuczak, Joanna, Samborski, Włodzimierz, Witowski, Janusz
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-29fabdbb774db9368a79df922efc1b5a777e54d1fc27031aae6b5b7d3c09a7f63
cites
container_end_page 294
container_issue 3
container_start_page 289
container_title Central-European journal of immunology
container_volume 43
creator Sikorska, Dorota
Rutkowski, Rafał
Łuczak, Joanna
Samborski, Włodzimierz
Witowski, Janusz
description While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of the disease and the response to anti-TNF- therapy. Twenty-one female RA patients qualified to receive anti-TNF- treatment were prospectively assessed before and after 12 weeks of therapy. Patients underwent full clinical and biochemical assessment. Disease activity was assessed by the Modified Disease Activity Scores (DAS28). Serum concentrations of adiponectin were measured with an immunoassay. The individuals were divided into two subgroups according to whether their baseline serum adiponectin was below or above the median value. The subgroups did not differ in basic demographic, anthropometric, and clinical parameters. Anti-TNF- treatment resulted in a significant clinical (DAS28) improvement in patients from both subgroups, but no significant differences between basal and post-treatment serum adiponectin concentrations were observed. However, patients with higher baseline adiponectin experienced a significant and more pronounced improvement in laboratory parameters of inflammation (ESR, CRP, neutrophil count, neutrophil-to-lymphocyte ratio). It is possible that adiponectin exerts systemic anti-inflammatory effects independently of the local activity of RA.
doi_str_mv 10.5114/ceji.2018.80048
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ae01864e67a34522a4fff246a2e38f6e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ae01864e67a34522a4fff246a2e38f6e</doaj_id><sourcerecordid>2154636287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-29fabdbb774db9368a79df922efc1b5a777e54d1fc27031aae6b5b7d3c09a7f63</originalsourceid><addsrcrecordid>eNpdkstu1DAUhiMEoqWwZocssWGTqW-xnQ0SqihUqmBBWVsnznHHoyQOdoI0j8WL8Ex4OqWirHz7zqfjo7-qXjO6aRiT5w53YcMpMxtDqTRPqlOmpKwl4_Jp2UuuatEyflK9yHlHqWqZaZ9XJ4I2xjAtTyv_DdM6EujDHCd0S5gIZAJkTtgHt8REoicDdDFBOexJwlzAjGSJBKYl1DdfLuvfv8iyxQTznpT6tMV1LHToCaRlm8IS8svqmYch46v79az6fvnx5uJzff3109XFh-vaSaOXmrceur7rtJZ91wplQLe9bzlH71jXgNYaG9kz77imggGg6ppO98LRFrRX4qy6Onr7CDs7pzBC2tsIwd5dxHRrS0_BDWgBy9iURKVByIZzkN57LhVwFMYrLK73R9e8diP2DqclwfBI-vhlClt7G39aVcaraFsE7-4FKf5YMS92DNnhMMCEcc2WM8WoaqSQBX37H7qLa5rKqArVSCUUN7pQ50fKpZhzQv_QDKP2kAd7yIM95MHe5aFUvPn3Dw_83wCIP3satCs</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2154636287</pqid></control><display><type>article</type><title>Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Sikorska, Dorota ; Rutkowski, Rafał ; Łuczak, Joanna ; Samborski, Włodzimierz ; Witowski, Janusz</creator><creatorcontrib>Sikorska, Dorota ; Rutkowski, Rafał ; Łuczak, Joanna ; Samborski, Włodzimierz ; Witowski, Janusz</creatorcontrib><description>While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of the disease and the response to anti-TNF- therapy. Twenty-one female RA patients qualified to receive anti-TNF- treatment were prospectively assessed before and after 12 weeks of therapy. Patients underwent full clinical and biochemical assessment. Disease activity was assessed by the Modified Disease Activity Scores (DAS28). Serum concentrations of adiponectin were measured with an immunoassay. The individuals were divided into two subgroups according to whether their baseline serum adiponectin was below or above the median value. The subgroups did not differ in basic demographic, anthropometric, and clinical parameters. Anti-TNF- treatment resulted in a significant clinical (DAS28) improvement in patients from both subgroups, but no significant differences between basal and post-treatment serum adiponectin concentrations were observed. However, patients with higher baseline adiponectin experienced a significant and more pronounced improvement in laboratory parameters of inflammation (ESR, CRP, neutrophil count, neutrophil-to-lymphocyte ratio). It is possible that adiponectin exerts systemic anti-inflammatory effects independently of the local activity of RA.</description><identifier>ISSN: 1426-3912</identifier><identifier>EISSN: 1644-4124</identifier><identifier>DOI: 10.5114/ceji.2018.80048</identifier><identifier>PMID: 30588174</identifier><language>eng</language><publisher>Poland: Termedia Publishing House</publisher><subject>adipocytokines ; Adiponectin ; anti-TNF-α treatment ; Clinical Immunology ; Inflammation ; Laboratories ; Neutrophils ; Patients ; Phenotypes ; Rheumatoid arthritis ; Serum levels ; Tumor necrosis factor-α</subject><ispartof>Central-European journal of immunology, 2018-01, Vol.43 (3), p.289-294</ispartof><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2018 Polish Society of Experimental and Clinical Immunology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-29fabdbb774db9368a79df922efc1b5a777e54d1fc27031aae6b5b7d3c09a7f63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305609/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2154636287?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30588174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sikorska, Dorota</creatorcontrib><creatorcontrib>Rutkowski, Rafał</creatorcontrib><creatorcontrib>Łuczak, Joanna</creatorcontrib><creatorcontrib>Samborski, Włodzimierz</creatorcontrib><creatorcontrib>Witowski, Janusz</creatorcontrib><title>Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis</title><title>Central-European journal of immunology</title><addtitle>Cent Eur J Immunol</addtitle><description>While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of the disease and the response to anti-TNF- therapy. Twenty-one female RA patients qualified to receive anti-TNF- treatment were prospectively assessed before and after 12 weeks of therapy. Patients underwent full clinical and biochemical assessment. Disease activity was assessed by the Modified Disease Activity Scores (DAS28). Serum concentrations of adiponectin were measured with an immunoassay. The individuals were divided into two subgroups according to whether their baseline serum adiponectin was below or above the median value. The subgroups did not differ in basic demographic, anthropometric, and clinical parameters. Anti-TNF- treatment resulted in a significant clinical (DAS28) improvement in patients from both subgroups, but no significant differences between basal and post-treatment serum adiponectin concentrations were observed. However, patients with higher baseline adiponectin experienced a significant and more pronounced improvement in laboratory parameters of inflammation (ESR, CRP, neutrophil count, neutrophil-to-lymphocyte ratio). It is possible that adiponectin exerts systemic anti-inflammatory effects independently of the local activity of RA.</description><subject>adipocytokines</subject><subject>Adiponectin</subject><subject>anti-TNF-α treatment</subject><subject>Clinical Immunology</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Rheumatoid arthritis</subject><subject>Serum levels</subject><subject>Tumor necrosis factor-α</subject><issn>1426-3912</issn><issn>1644-4124</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkstu1DAUhiMEoqWwZocssWGTqW-xnQ0SqihUqmBBWVsnznHHoyQOdoI0j8WL8Ex4OqWirHz7zqfjo7-qXjO6aRiT5w53YcMpMxtDqTRPqlOmpKwl4_Jp2UuuatEyflK9yHlHqWqZaZ9XJ4I2xjAtTyv_DdM6EujDHCd0S5gIZAJkTtgHt8REoicDdDFBOexJwlzAjGSJBKYl1DdfLuvfv8iyxQTznpT6tMV1LHToCaRlm8IS8svqmYch46v79az6fvnx5uJzff3109XFh-vaSaOXmrceur7rtJZ91wplQLe9bzlH71jXgNYaG9kz77imggGg6ppO98LRFrRX4qy6Onr7CDs7pzBC2tsIwd5dxHRrS0_BDWgBy9iURKVByIZzkN57LhVwFMYrLK73R9e8diP2DqclwfBI-vhlClt7G39aVcaraFsE7-4FKf5YMS92DNnhMMCEcc2WM8WoaqSQBX37H7qLa5rKqArVSCUUN7pQ50fKpZhzQv_QDKP2kAd7yIM95MHe5aFUvPn3Dw_83wCIP3satCs</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Sikorska, Dorota</creator><creator>Rutkowski, Rafał</creator><creator>Łuczak, Joanna</creator><creator>Samborski, Włodzimierz</creator><creator>Witowski, Janusz</creator><general>Termedia Publishing House</general><general>Polish Society of Experimental and Clinical Immunology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180101</creationdate><title>Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis</title><author>Sikorska, Dorota ; Rutkowski, Rafał ; Łuczak, Joanna ; Samborski, Włodzimierz ; Witowski, Janusz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-29fabdbb774db9368a79df922efc1b5a777e54d1fc27031aae6b5b7d3c09a7f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>adipocytokines</topic><topic>Adiponectin</topic><topic>anti-TNF-α treatment</topic><topic>Clinical Immunology</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Rheumatoid arthritis</topic><topic>Serum levels</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sikorska, Dorota</creatorcontrib><creatorcontrib>Rutkowski, Rafał</creatorcontrib><creatorcontrib>Łuczak, Joanna</creatorcontrib><creatorcontrib>Samborski, Włodzimierz</creatorcontrib><creatorcontrib>Witowski, Janusz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Central-European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sikorska, Dorota</au><au>Rutkowski, Rafał</au><au>Łuczak, Joanna</au><au>Samborski, Włodzimierz</au><au>Witowski, Janusz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis</atitle><jtitle>Central-European journal of immunology</jtitle><addtitle>Cent Eur J Immunol</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>43</volume><issue>3</issue><spage>289</spage><epage>294</epage><pages>289-294</pages><issn>1426-3912</issn><eissn>1644-4124</eissn><abstract>While adiponectin is typically viewed as an anti-inflammatory mediator, such an activity of adiponectin in rheumatoid arthritis (RA) is not so obvious. In the present study we examined whether serum levels of adiponectin reflect the clinical phenotype of RA patients and/or correlate with severity of the disease and the response to anti-TNF- therapy. Twenty-one female RA patients qualified to receive anti-TNF- treatment were prospectively assessed before and after 12 weeks of therapy. Patients underwent full clinical and biochemical assessment. Disease activity was assessed by the Modified Disease Activity Scores (DAS28). Serum concentrations of adiponectin were measured with an immunoassay. The individuals were divided into two subgroups according to whether their baseline serum adiponectin was below or above the median value. The subgroups did not differ in basic demographic, anthropometric, and clinical parameters. Anti-TNF- treatment resulted in a significant clinical (DAS28) improvement in patients from both subgroups, but no significant differences between basal and post-treatment serum adiponectin concentrations were observed. However, patients with higher baseline adiponectin experienced a significant and more pronounced improvement in laboratory parameters of inflammation (ESR, CRP, neutrophil count, neutrophil-to-lymphocyte ratio). It is possible that adiponectin exerts systemic anti-inflammatory effects independently of the local activity of RA.</abstract><cop>Poland</cop><pub>Termedia Publishing House</pub><pmid>30588174</pmid><doi>10.5114/ceji.2018.80048</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1426-3912
ispartof Central-European journal of immunology, 2018-01, Vol.43 (3), p.289-294
issn 1426-3912
1644-4124
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ae01864e67a34522a4fff246a2e38f6e
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects adipocytokines
Adiponectin
anti-TNF-α treatment
Clinical Immunology
Inflammation
Laboratories
Neutrophils
Patients
Phenotypes
Rheumatoid arthritis
Serum levels
Tumor necrosis factor-α
title Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T14%3A45%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20adiponectin%20as%20a%20predictor%20of%20laboratory%20response%20to%20anti-TNF-%CE%B1%20therapy%20in%20rheumatoid%20arthritis&rft.jtitle=Central-European%20journal%20of%20immunology&rft.au=Sikorska,%20Dorota&rft.date=2018-01-01&rft.volume=43&rft.issue=3&rft.spage=289&rft.epage=294&rft.pages=289-294&rft.issn=1426-3912&rft.eissn=1644-4124&rft_id=info:doi/10.5114/ceji.2018.80048&rft_dat=%3Cproquest_doaj_%3E2154636287%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-29fabdbb774db9368a79df922efc1b5a777e54d1fc27031aae6b5b7d3c09a7f63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2154636287&rft_id=info:pmid/30588174&rfr_iscdi=true